Insmed shelves Brinsupri in skin disease after mid-stage flop

Elizabeth Cairns / endpoints - Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill in sinus inflammation at the end of last year. The ...

AI Summary: Insmed announced it will halt development of Brinsupri for a dermatologic indication following disappointing mid‑stage trial results. Company commentary stressed the skin setback does not negate Brinsupri’s potential in pulmonary indications, but investors and clinicians will understandably ask for clearer signs of life before buying the comeback story.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 8 days

FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 2 months

First-in-human trial primes immune system to accept donor livers / 6 wks

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days

Avalyn upsizes IPO to raise cash for lung drug trials / 29 days

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio / 2 months